Matrix metalloproteinase levels in the drained dialysate reflect the peritoneal solute transport rate: A multicentre study in Japan

Nephrology Dialysis Transplantation

Volumn 26, Issue 5, 2011, Pages 1695-1701

  Hirahara, Ichiro ^a   Inoue, Makoto ^a   Umino, Tetsuo ^a   Saito, Osamu ^a   Muto, Shigeaki ^a   Kusano, Eiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

matrix metalloproteinase; peritoneal dialysis; peritoneal injury; peritoneal solute transport

Indexed keywords

CREATININE; GELATINASE A; GLUCOSE; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ABDOMINAL DRAINAGE; ADULT; AGED; ARTICLE; DIALYSATE LEVEL; FEMALE; HUMAN; JAPAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEMBRANE TRANSPORT; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEAL SOLUTE TRANSPORT; PRIORITY JOURNAL; TRANSPORT KINETICS;

AGED; BIOLOGICAL MARKERS; DIALYSIS SOLUTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEUM; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 79955613662     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq593     Document Type: Article

References (20)

1. Gandhi VC, Humayun HM, Ing TS et al. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980; 140: 1201-1203 (Pubitemid 10048816)
2. Schmidt DW, Flessner MF. Pathogenesis and treatment of encapsulat-ing peritoneal sclerosis: basic and translational research. Perit Dial Int 2008; 28: S10-S15
3. Kawaguchi Y, Saito A, Kawanishi H et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005; 25: S83-S95 (Pubitemid 41600364)
4. Hirahara I, Kusano E, Yanagiba S et al. Peritoneal injury by methyl-glyoxal in peritoneal dialysis. Perit Dial Int 2005; 26: 380-392
5. Twardowski ZJ, Nolph KD, Khanna R et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7: 138-147 (Pubitemid 18014430)
6. Jones CL. Matrix degradation in renal disease. Nephrology 1996; 2: 13-23 (Pubitemid 126439724)
7. Hirahara I, Inoue M, Okuda K et al. The potential of matrix metallo-proteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis-a multicentre study in Japan. Nephrol Dial Trans-plant 2007; 22: 560-567 (Pubitemid 46189902)
8. Hirahara I, Umeyama K, Urakami K et al. Serial analysis of matrix metalloproteinase-2 in dialysate of rat sclerosing peritonitis models. Clin Exp Nephrol 2001; 5: 103-108 (Pubitemid 32675036)
9. Zweers MM, de Waart DR, Smit W et al. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. JLab Clin Med 1999; 134: 124-132 (Pubitemid 29375441)
10. Coester AM, Smit W, Struijk DG et al. Peritoneal function in clinical practice: the importance of follow-up and its measurement in patients. Recommendations for patient information and measurement of peri-toneal function. NDT Plus 2009; 2: 104-110
11. Kaku Y, Nohara K, Tsutsumi Y et al. The relationship among the markers of peritoneal function such as PET, MMP-2, IL-6 etc, in pediatric and adolescent PD patients. Jin To Touseki 2004; 57(Suppl): 296-298 (in Japanese)
12. Hirahara I, Umeyama K, Shofuda K et al. Increase of matrix metal-loproteinase-2 in dialysate of rat sclerosing encapsulating peritonitis model. Nephrology 2002; 7: 161-169 (Pubitemid 35015367)
13. Hirahara I, Ogawa Y, Kusano E et al. Activation of matrix metallo-proteinase-2 causes peritoneal injury during peritoneal dialysis in rats. Nephrol Dial Transplant 2004; 19: 1732-1741 (Pubitemid 38961381)
14. Ro Y, Hamada C, Inaba M et al. Inhibitory effects of matrix metal-loproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 2007; 22: 2838-2848 (Pubitemid 350093438)
15. Soccal PM, Gasche Y, Pache JC et al. Matrix metalloproteinases cor-relate with alveolar-capillary permeability alteration in lung ische-mia-reperfusion injury. Transplantation 2000; 70: 998-1005
16. Swann K, Berger J, Sprague SM et al. Peripheral thermal injury causes blood-brain barrier dysfunction and matrix metalloproteinase (MMP) expression in rat. Brain Res 2007; 1129: 26-33 (Pubitemid 46048776)
17. Giebel SJ, Menicucci G, McGuire PG et al. Matrix metalloprotei-nases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 2005; 85: 597-607 (Pubitemid 40675441)
18. Margetts PJ, Bonniaud P, Liu L et al. Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. JAm Soc Nephrol 2005; 16: 425-436 (Pubitemid 41725138)
19. Hirahara I, Ishibashi Y, Kaname S et al. Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant 2009; 24: 437-447
20. Del Peso G, Jiménez-Heffernan JA, Bajo MA et al. Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int Suppl 2008; 108: S26-S33 (Pubitemid 351466514)